Graham Capital Management L.P. Has $1.21 Million Stake in IQVIA Holdings Inc. $IQV

Key Points

• Graham Capital Management L.P. has reduced its stake in IQVIA Holdings Inc. by 38.5%, selling 4,316 shares and now holding a total of 6,885 shares valued at approximately $1,214,000.
• Other hedge funds have increased their positions in IQVIA significantly, with Pacer Advisors Inc. growing its stake by 5,036.1% and JPMorgan Chase & Co. increasing by 45.7%.
• Despite recent adjustments in holdings, IQVIA's stock is up 0.2%, with its shares opening at $184.05 and a market capitalization of $31.29 billion.

Graham Capital Management L.P. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,885 shares of the medical research company's stock after selling 4,316 shares during the quarter. Graham Capital Management L.P.'s holdings in IQVIA were worth $1,214,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of IQV. Sowell Financial Services LLC purchased a new position in shares of IQVIA during the 1st quarter valued at approximately $305,000. Mather Group LLC. grew its holdings in IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock worth $136,000 after acquiring an additional 350 shares during the period. Private Advisor Group LLC boosted its position in IQVIA by 11.6% during the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock worth $958,000 after purchasing an additional 566 shares in the last quarter. Park Avenue Securities LLC lifted its position in shares of IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after acquiring an additional 1,562 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after buying an additional 3,398 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on IQV. JPMorgan Chase & Co. reduced their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Truist Financial raised their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on IQVIA in a research note on Wednesday, September 3rd. Finally, William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $229.86.

IQVIA Stock Up 0.1%

Shares of IQV stock traded up $0.12 on Monday, reaching $187.80. 846,675 shares of the company were exchanged, compared to its average volume of 1,917,812. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $248.03. The company has a 50-day moving average of $179.88 and a 200-day moving average of $167.23. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $31.93 billion, a price-to-earnings ratio of 27.07, a PEG ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.